Table 2.
Primary and secondary endpoint results after 4 weeks of follow-up in the FAS, n (%).
| Items | XSN group (n=328) | Mexiletine group (n=336) | Placebo group (n=165) | Rate difference,% (95% CI) | P |
|---|---|---|---|---|---|
| Primary endpoints | |||||
| SER | 150 (45.73) | 137 (40.77) | 24 (14.55) | ||
| ER | 66 (20.12) | 75 (22.32) | 21 (12.73) | ||
| TER | 216 (65.85) | 212 (63.10) | 45 (27.27) | 38.58 (30.07–47.10) | <0.0001 |
| Secondary endpoints | |||||
| Palpitation | |||||
| SER | 163 (52.41) | 137(41.03) | 32 (20.65) | ||
| ER | 91 (29.26) | 81 (24.85) | 52 (33.55) | ||
| TER | 254 (81.67) | 218 (66.88) | 84 (54.2) | <0.0001 | |
| Chest discomfort | |||||
| SER | 189 (60.77) | 174 (53.37) | 57 (36.78) | ||
| ER | 56 (18.01) | 48 (14.72) | 29 (18.71) | ||
| TER | 245 (78.78) | 222 (68.09) | 86 (55.49) | <0.0001 |
FAS, full analysis set; CI, confidence interval; SER, significantly effective response; ER, effective response; TER, total effective response; rate difference, rate of TER in XSN group − rate of TER in placebo group; P, XSN group vs. placebo group.